Page 3«..2345..1020..»

Starpharma to Webcast Live at Life Sciences Investor Forum June 24th

By Dr. Matthew Watson

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com

Originally posted here:
Starpharma to Webcast Live at Life Sciences Investor Forum June 24th

To Read More: Starpharma to Webcast Live at Life Sciences Investor Forum June 24th
categoriaGlobal News Feed commentoComments Off on Starpharma to Webcast Live at Life Sciences Investor Forum June 24th | dataJune 25th, 2021
Read All

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

By Dr. Matthew Watson

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

Read the original:
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

To Read More: Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD
categoriaGlobal News Feed commentoComments Off on Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD | dataJune 25th, 2021
Read All

PAOG Targets $18 Billion Market Opportunity With New CBD Nutraceutical To Be Packaged By ALKM And Marketed By USMJ

By Dr. Matthew Watson

Sandusky, Ohio, June 24, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today published a CBD Nutraceuticals Business Development Update. PAOG expects to generate revenue this year from its CBD Nutraceuticals.

Read the original post:
PAOG Targets $18 Billion Market Opportunity With New CBD Nutraceutical To Be Packaged By ALKM And Marketed By USMJ

To Read More: PAOG Targets $18 Billion Market Opportunity With New CBD Nutraceutical To Be Packaged By ALKM And Marketed By USMJ
categoriaGlobal News Feed commentoComments Off on PAOG Targets $18 Billion Market Opportunity With New CBD Nutraceutical To Be Packaged By ALKM And Marketed By USMJ | dataJune 25th, 2021
Read All

Mountain Valley MD Provides Update on Key Strategic Initiatives: Patent Award, FDA Collaborative Research Agreement, Cold Chain, Dose Sparing,…

By Dr. Matthew Watson

TORONTO, June 24, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA:20MP) (OTCQB: MVMDF) is pleased to provide an update on the status of key initiatives:

Read the original here:
Mountain Valley MD Provides Update on Key Strategic Initiatives: Patent Award, FDA Collaborative Research Agreement, Cold Chain, Dose Sparing,...

To Read More: Mountain Valley MD Provides Update on Key Strategic Initiatives: Patent Award, FDA Collaborative Research Agreement, Cold Chain, Dose Sparing,…
categoriaGlobal News Feed commentoComments Off on Mountain Valley MD Provides Update on Key Strategic Initiatives: Patent Award, FDA Collaborative Research Agreement, Cold Chain, Dose Sparing,… | dataJune 25th, 2021
Read All

Axiom Presents "Unified Platforms: How to Address the Complexity of Oncology Studies to Better Support Your Sites" at Clinical Operations in…

By Dr. Matthew Watson

TORONTO, June 24, 2021 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting on June 24, 2021, at the Clinical Operations in Oncology Trials Conference. The virtual event consists of two streams of sessions welcoming experts from across the industry to discuss the latest innovations in technology, regulatory affairs and explore new opportunities to run successful clinical trials.

Read the rest here:
Axiom Presents "Unified Platforms: How to Address the Complexity of Oncology Studies to Better Support Your Sites" at Clinical Operations in...

To Read More: Axiom Presents "Unified Platforms: How to Address the Complexity of Oncology Studies to Better Support Your Sites" at Clinical Operations in…
categoriaGlobal News Feed commentoComments Off on Axiom Presents "Unified Platforms: How to Address the Complexity of Oncology Studies to Better Support Your Sites" at Clinical Operations in… | dataJune 25th, 2021
Read All

Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects

By Dr. Matthew Watson

Oculogica receives ground-breaking patent to assess CTE via its eye-tracking technology. Oculogica receives ground-breaking patent to assess CTE via its eye-tracking technology.

Read this article:
Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects

To Read More: Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects
categoriaGlobal News Feed commentoComments Off on Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects | dataJune 25th, 2021
Read All

OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

By Dr. Matthew Watson

NANTES, France, June 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

Read more:
OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

To Read More: OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
categoriaGlobal News Feed commentoComments Off on OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting | dataJune 25th, 2021
Read All

Top liver disease conference showcases positive clinical data from Yaqrit’s technologies

By Dr. Matthew Watson

Top liver disease conference showcases positive clinical data from Yaqrit’s technologies

Read more:
Top liver disease conference showcases positive clinical data from Yaqrit’s technologies

To Read More: Top liver disease conference showcases positive clinical data from Yaqrit’s technologies
categoriaGlobal News Feed commentoComments Off on Top liver disease conference showcases positive clinical data from Yaqrit’s technologies | dataJune 25th, 2021
Read All

Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and…

By Dr. Matthew Watson

SAN DIEGO, June 24, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that following its receipt of EUA approval from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under registration number “OFICIO: CAS/10720/2021”, it is establishing a local “Sorrento Mexico Ltd” subsidiary to manage commercial operations in Mexico.

See the article here:
Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and...

To Read More: Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and…
categoriaGlobal News Feed commentoComments Off on Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and… | dataJune 25th, 2021
Read All

Lowell Farms to Webcast Live at 2021 VirtualInvestorConferences.com on June 29

By Dr. Matthew Watson

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Original post:
Lowell Farms to Webcast Live at 2021 VirtualInvestorConferences.com on June 29

To Read More: Lowell Farms to Webcast Live at 2021 VirtualInvestorConferences.com on June 29
categoriaGlobal News Feed commentoComments Off on Lowell Farms to Webcast Live at 2021 VirtualInvestorConferences.com on June 29 | dataJune 25th, 2021
Read All

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

By Dr. Matthew Watson

FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced the initiation of patient dosing in the AVIATION Trial, a Phase 1b clinical trial evaluating TERN-201, an orally-administered, highly selective inhibitor of vascular adhesion protein-1 (VAP-1) in patients with NASH.

See more here:
Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

To Read More: Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
categoriaGlobal News Feed commentoComments Off on Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201 | dataJune 25th, 2021
Read All

Adverum Announces Changes to Management Team

By Dr. Matthew Watson

-- Christopher J. DeRespino appointed acting CFO ---- Peter Soparkar appointed COO --

More here:
Adverum Announces Changes to Management Team

To Read More: Adverum Announces Changes to Management Team
categoriaGlobal News Feed commentoComments Off on Adverum Announces Changes to Management Team | dataJune 25th, 2021
Read All

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

By Dr. Matthew Watson

Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company’s First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company’s First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor

View post:
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

To Read More: Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
categoriaGlobal News Feed commentoComments Off on Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1 | dataJune 25th, 2021
Read All

Bioventus Invests in Vaporox

By Dr. Matthew Watson

Ultrasonic Technology to Heal Diabetic Foot Ulcers Ultrasonic Technology to Heal Diabetic Foot Ulcers

See original here:
Bioventus Invests in Vaporox

To Read More: Bioventus Invests in Vaporox
categoriaGlobal News Feed commentoComments Off on Bioventus Invests in Vaporox | dataJune 25th, 2021
Read All

Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with…

By Dr. Matthew Watson

Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ?50% PD-L1 expression

See the original post here:
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with...

To Read More: Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with…
categoriaGlobal News Feed commentoComments Off on Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with… | dataJune 25th, 2021
Read All

Avicanna Announces Results of Annual General Meeting and Provides Corporate Update

By Dr. Matthew Watson

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

See more here:
Avicanna Announces Results of Annual General Meeting and Provides Corporate Update

To Read More: Avicanna Announces Results of Annual General Meeting and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Avicanna Announces Results of Annual General Meeting and Provides Corporate Update | dataJune 25th, 2021
Read All

Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149

By Dr. Matthew Watson

Timeline Guidance for Both Programs Confirmed

More here:
Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149

To Read More: Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149
categoriaGlobal News Feed commentoComments Off on Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149 | dataJune 25th, 2021
Read All

Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell…

By Dr. Matthew Watson

Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Go here to read the rest:
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell...

To Read More: Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell…
categoriaGlobal News Feed commentoComments Off on Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell… | dataJune 25th, 2021
Read All

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

By Dr. Matthew Watson

Follow this link:
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

To Read More: Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
categoriaGlobal News Feed commentoComments Off on Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates | dataJune 25th, 2021
Read All

Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes

By Dr. Matthew Watson

Visit link:
Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes

To Read More: Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
categoriaGlobal News Feed commentoComments Off on Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes | dataJune 25th, 2021
Read All

Page 3«..2345..1020..»